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Photochemistry harbours a wealth of exciting reagents and reactions that represent an untapped 
potential for applications in protein modification. This Concept article by J. P. Holland et al. 
introduces the key ideas that underpin photoradiosynthesis, and surveys the chemical scope and 
associated mechanistic attributes of different photochemical processes that hold promise for future 







The ability to modify biologically active molecules such as antibodies with drug molecules, 
fluorophores or radionuclides is crucial in drug discovery and target identification. Classic 
chemistry used for protein functionalisation rely almost exclusively on thermochemically 
mediated reactions. Our recent experiments have begun to explore the use of photochemistry to 
affect rapid and efficient protein functionalisation. This article introduces some of the principles 
and objectives of using photochemically activated reagents for protein ligation. The concept of 
simultaneous photoradiosynthesis of radiolabelled antibodies for use in molecular imaging is 
introduced as a working example. Notably, the goal of producing functionalised proteins in the 
absence of pre-association (non-covalent ligand-protein binding) introduces requirements that are 
distinct from the more regular use of photoactive groups in photoaffinity labelling. With this in 
mind, the chemistry of thirteen different classes of photoactivatable reagents that react via the 
formation of intermediate carbenes, electrophiles, dienes or radicals, is assessed.  
 








Photochemistry harbours a rich array of reactions that represent a relatively untapped resource for 
potential applications in the synthesis of functionalised biological molecules like antibody-drug 
conjugates (ADCs), or radiolabelled proteins for imaging or radioimmunotherapy (RIT).[1,2] While 
recent advances have been made in bioorthogonal[3] and site-specific modification of biologically 
active molecules,[4–7] the majority of tools that are currently used to link payloads including 
cytotoxic drugs, radionuclides or fluorophores to proteins rely on thermochemically-mediated, 
multiple-step conjugation reactions.[8–13]  
Photochemical methods for labelling proteins were first introduced in 1962 by Westheimer 
and co-workers.[14] Subsequently, the wide range of photoaffinity probes (PAPs) were introduced 
and a selection of representative photoactive groups used in photo affinity labelling (PAL) is 
shown in Figure 1.[15–27] Nowadays, photoaffinity labelling (PAL) is an indispensable tool for 
probing the location, structure, and function of different biological molecules in vitro and in 
vivo.[28–32] Specific applications of PAL in target identification,[33,34] drug discovery,[35,36] protein 
cross-linking,[37] chemical proteomics,[38,39] and in the generation of fluorescent probes[40] were the 
subjects of several excellent reviews. 
 
 






The extreme reactivity of many photo-induced intermediates (typically radicals, carbenes 
and nitrenes) means that PAL usually requires pre-association of the photoactive ligand with the 
target protein. Mechanistically, PAL normally entails functionalising a molecule that binds to a 
target with high affinity and selectively, with a photoactive group.[24,28] Pre-association to form a 
non-covalent ligand-protein complex effectively ensures that after irradiation with light, the photo-
induced intermediates react preferentially in a pseudo-first order intramolecular reaction with the 
protein of interest, avoiding non-productive background reactions (with water, salts, oxygen etc). 
However, for our purposes of using photochemistry as a general tool for the synthesis of 
bioconjugate ADCs and radioimmunoconjugates, the reaction between a photo-induced 
intermediate and the biologically active molecule should be bimolecular. Here, we focus on 
photochemical reactions that have potential to be used in protein labelling without pre-association.  
As a proof-of-principle, our group recently introduced an alternative approach for the 
synthesis of radiolabelled antibodies (mAbs) that combined a photochemical activation step with 
simultaneous radiolabelling to produce viable radiotracers for immuno-positron emission 
tomography (immuno-PET).[41–45] Termed, ‘photoradiosynthesis’, the concept involves a light-
induced activation of a photoactive substrate to form a highly reactive electrophile that reacts in 
situ with nucleophilic amino acid residues (primarily the e-NH2 side-chain group of lysine) on a 
protein (Scheme 1). This combination of photochemistry and radiochemistry was inspired by, i) 
the need to perform functionalisation reactions as quickly as possible when working with 
radionuclides that have short half-lives,[46] ii) eliminating the isolation and characterisation of a 
functionalised intermediate prior to the radiolabelling step, iii) the development of a radiolabelling 




used to stabilise mAbs in clinical grade products. Notably, the use of reliable, photochemically-
initiated bioconjugation reactions is not restricted to the synthesis of radioactive compounds but is 
potentially useful in ADC synthesis and beyond.  
 
Scheme 1. Illustration of the conventional (top) and simultaneous (bottom) route for the 
conjugation and radiolabelling of biologically active molecules. The concept of 
‘photoradiosynthesis’ involves the simultaneous, one-pot photochemically induced 
functionalisation and radiolabelling of a biologically active molecule in situ, without the need for 
pre-purification.[13,41–45]  
 
This article begins with an illustration of the key aspects of photoradiosynthesis and then 




processes or hold potential for future applications. For simplification, we focus on conjugation to 
mAbs, but in principle, many of the reactions described could be adapted for use with other 
biologically active molecules. 
 
Photoradiosynthesis of radiolabelled antibodies 
Given time constraints of working with radionuclides that have short half-lives, it is perhaps 
surprising that the combination of photochemistry with radiochemistry has received little attention. 
Sykes et al. were the first to report photoactivation of an antibody to generate reactive sulfhydryl 
groups which facilitated 99mTc and 188Re radiolabelling.[47,48] Stalteri and Mather also used the 
same approach.[49] Photoactive 18F-based reagents were first reported by Hashizume et al. who 
prepared [18F]pentafluorophenyl azide via isotopic exchange.[50] Soon after, Wester et al. reported 
the radiosynthesis of 4-azidophenacyl-[18F]fluoride ([18F]APF) and found that upon irradiation 
with UV light, radiolabelled proteins (including immunoglobulins) could be isolated in ~15% to 
~35% radiochemical yield (RCY).[51] Lange et al. radiolabelled an oligonucleotide aptamer with 
3-azido-5-nitrobenzyl-[18F]fluoride.[52] In a series of articles, Pandurangi et al. prepared 
photoactivatable complexes of 109Pd, Re, and 99mTc.[53–56] Nishikawa et al. used photochemistry to 
radiolabel plasmid DNA with 111In 4-(p-azidosalicylamido)butylamine 
diethylenetriaminepentaacetic acid (DTPA-ASBA).[57] In addition, other groups have prepared 
various photoactivatable ligands radiolabelled with 3H[58], 14C[59] and 125I[60] for studying binding 
site interactions on various plasma proteins.[61] 
 Our lab recently reported the synthesis, radiolabelling and bimolecular coupling of 
photoactivatable chelates bearing the photoactive aryl azide (ArN3) group to antibodies for use in 




traditional, thermally-mediated reactions[10–13] to a photo-initiated reaction allowed us to produce 
radiolabelled mAbs in a simultaneous (one-pot) process directly from fully formulated antibodies 
(including trastuzumab which targets the human epidermal growth-factor receptor 2 [HER2/neu], 
and onartuzumab which binds to the human hepatocyte growth-factor receptor [c-MET]). 
Radiochemical yields (RCYs) of the isolated radiotracers varied substantially depending on the 
nature of the chelate and the radionuclide using narrow-band light sources with peak emissions at 
365 or 395 nm. The highest RCYs were obtained using [89Zr][ZrDFO-ArN3]+ (89Zr-5+) where 
between 67% – 88% of the radioactivity was recovered in the mAb fraction after purification. 
Standard cellular-based binding assays and radiochromatography using size-exclusion methods 
confirmed that the antibodies remained monomeric, were stable over time, and retained 
immunoreactivity and specificity for the target antigens. Immuno-PET imaging in tumour-bearing 
mice and biodistribution studies ex vivo also demonstrated that the photoradiosynthetic approach 





Figure 2. Structures of various macrocyclic (left) and acyclic (right) chelates that were synthesised 
for photoradiosynthesis of 68Ga-, 89Zr- and 111In-radiolabelled mAbs.[41–45] Notably, this range of 
chelates is also suitable for complexation of other radioactive metal ions including, but not limited 
to, 64Cu for positron emission tomography imaging, 67Cu and 177Lu for single-photon emission 
computed tomography (SPECT) imaging and b-therapy, and 225Ac for a-particle therapy.[62,63]  
 
Figure 3. Representative planar and maximum intensity projection (MIP) immuno-PET images 
showing the distribution and specific tumour-uptake of [89Zr]ZrDFO-azepin-trastuzumab in 
athymic nude mice bearing subcutaneous SK-OV-3 ovarian cancer tumours. H = heart, L = liver, 
T = tumour.[42] 
 
 Interesting features of photoradiosynthesis include: i) rapid reaction kinetics – the 
radiolabelling, photo-initiation and conjugation steps occur simultaneously and are complete in 
<10 min. Reaction rates were shown to be directly proportional to light intensity where high photon 
flux leads to faster photoactivation. This observation presents the intriguing possibility that with a 
more intense light source, the photochemically induced bioconjugation step could potentially be 
completed in seconds – literally, in a flash. ii) Chemoselectivity – photoactivation of an ArN3 




1A2 state) singlet aryl nitrene which undergoes rapid cyclisation to a benzazirine and rearrangement 
to the powerful ketenimine electrophile. Empirical data and computational studies have shown that 
this ketenimine species undergoes preferential nucleophilic attack by amines (lysine).[64,65] 
Importantly, the rate of bimolecular reaction with protein-bound lysine residues is competitive 
with, and in the case of the 89Zr-5+ complex, exceeds that of background quenching reactions with 
water, which leads to productive functionalisation of mAbs.[42] iii) The photochemical reaction 
with ArN3 groups tolerates oxygen in aqueous conditions, and operates at a pH range (ca. 7 – 9) 
and is compatible with many formulation buffers used to stabilise clinical grade preparations of 
many mAbs. iv) Photoactivation occurs at wavelengths where the protein or biomolecule does not 
absorb. Hence, the photolysis reaction does not damage the underlying structure and function of 
the biological vector.[44] v) The photoradiosynthesis process is amenable to full automation which 
may streamline the efforts required to produce functionalised proteins. vi) The one-pot procedure 
allows us to go directly from the formulated mAb to a formulated radiolabelled product, without 
isolating intermediates. In accordance with most regulatory authorities including the United States 
Federal Drug Administration, European Medicines Agency, and Swiss Medic, the functionalised 
intermediate is classified as a New Molecular Entities (NMEs). While some groups performing 
immuno-PET have managed to circumvent the requirement to provide full absorption, distribution, 
metabolism, excretion and toxicological (ADME-tox) tests on the functionalised (non-
radiolabelled) intermediate, this is not always possible. Hence, methods that eliminate the isolation 
of an intermediate have the potential to reduce the practical difficulties and extreme (and often 




The success of the photoradiosynthesis approach (vide infra) prompted us to explore a 
broader scope of photochemical reactions for potential synthesis of ADCs and 
radioimmunoconjugates.  
 
Photoactive reagents that produce carbenes 
Diazo compounds  
Light-induced generation of carbenes starting from diazo acetyl were among the first reagents to 
be employed in PAL.[14] Irradiation of diazo acetals, and compounds containing 2-diazo-3-
trifluoropropionyl,[21] diazocyclopentadienyl,[25] alky diazomalonyl,[25] or 
diazocyclohexadienones[27] liberates N2(g) and produces carbene species that have lifetimes on the 
order of nanoseconds (Scheme 2). Initially, singlet carbenes are produced which can react with 
fundamental chemical groups (i.e. alcohols and alkenes), and also undergo C-H bond insertion to 
form stable covalent products with bimolecular rate constants in the range, k2 = 107 – 109 M-1 s-
1.[66] Not all carbene generating reagents are useful for bioconjugation reactions or PAL. For 
instance, reagents that generate alkyl carbenes and contain b-H atoms can also undergo rapid 
hydrogen atom transfer to give an alkene product.[67,68] In addition, decomposition reactions can 
also compete with the photochemistry. As an example, a-keto-diazo compounds are susceptible 
to Wolff-type rearrangements which can degrade the starting materials and form ketenes which 
undergo further nucleophilic attack by water to give carboxylic acids.[20] Compounds that lack b-
H atoms, or those that have aryl substituents (vide infra) which stabilise the singlet carbene can 
circumvent some of these reaction channels that would compete with productive conjugation to 






Scheme 2. Illustration of the reaction of diazo compounds with an antibody. 
  
Due to low energy differences between the singlet and triplet states (~30 – 40 kJ mol-1), 
singlet carbenes can undergo more facile intersystem crossing to produce more stable triplet 
species. Triplet carbenes do not typically insert into O-H bonds because the process is spin-
forbidden and would generate an unstable RO• radical but they do insert into C-H bonds. Triplet 
carbenes can also undergo dimerisation reactions which would quench any potential 
functionalisation of proteins. Since proteins do not normally contain triplet diradicals, productive 
bioconjugation pathways primarily rely on the reactivity of the singlet carbene species.[66]  
 The extreme reactivity of singlet carbenes means that reactions often proceed at rates that 
approach the limits of diffusion. For traditional PAL using ligand-protein pre-association, carbenes 
have the advantage that they can insert rapidly into protein C-H bonds, thereby producing a 
bioconjugate where the ligand covalently attaches to the protein at (or close to) the ligand binding 
site. However, this high reactivity also means that pre-association to form an initial non-covalent 
ligand-protein complex is a prerequisite for successful coupling. The very short lifetime of non-
stabilised singlet carbenes is a fundamental limitation when using these reagents in bimolecular 
conjugation reactions with systems that do not pre-associate. Another disadvantage of diazo 




dinitrogen. Diazo compounds and diazonium salts often require careful control of the reaction 
conditions (temperature, pH etc) and accessing ‘bench stable’ reagents is not always possible. 
 
Aryl diazirines  
To circumvent some of the issues associated with low stability of diazo compounds and diazonium 
salts, the photochemical properties of a range of alternative photoactive groups were explored. 
Smith and Knowles were the first to explore the use of aryl diazirines for PAL in 1973.[20] Aryl 
diazirines have increased thermal stability, are relatively simple to synthesise, exhibit efficient 
photoactivation properties, and after photo-induced loss of N2(g), produce highly reactive singlet 
carbenes (Scheme 3).[69,70] A major advance in the use of aryl diazirines for PAL was achieved in 
1980 when Brunner et al. reported the efficient synthesis and photochemical properties of para-
substituted trifluoromethyl phenyl diazirines – reagents which have become the mainstay of most 
modern applications of PAL.[23]  
 
Scheme 3. Illustration of the reaction of aryl diazirines with an antibody. 
 
Recent examples which highlight the synthetic versatility of incorporating trifluoromethyl 
phenyl diazirines into complex structures include (Figure 4): the synthesis of a photoactivatable 




derivative of the artificial sweetener saccharin for potential use in elucidating the mechanisms that 
underpin our sense of taste (compound 9)[72]; and a photoactivatable version of the heat-shock 
protein 90 (HSP90) inhibitor novobiocin (compound 10) for elucidating the mechanism of drug 
binding to the C-terminal protein domain.[73] 
 
Figure 4. Structures of recent photoactive probes used to study the mechanisms of action for 
different anti-cancer drugs and artificial protein substrates.[71–73] 
 
Aliphatic diazirines 
In contrast to aryl diazirines, the use of aliphatic diazirines remains limited. The reviews by Das[66] 
and by Hill and Robertson[74] provide comprehensive overviews of aliphatic diazirine chemistry 
and their applications in drug/target discovery. In the context of PAL, aliphatic diazirines have 
received less attention that other diazirine species. Reasons include the facts that, i) photolysis of 
aliphatic diazirines produces comparatively long-lived intermediates that can diffuse from the site 
of generation and can complicate data interpretation, ii) deactivation by 1,2-hydrogen (b-H) atom 
rearrangement, and iii) the tendency of aliphatic diazirines to form the diazo compound upon 




from water. However, in our context of developing a generic method to label proteins in a 
bimolecular fashion, diffusion of the longer-lived intermediates is not relevant. 
 In an elegant example that demonstrates how photoactive probes can be used as tools in 
the biological sciences, Li et al. developed a processed termed ‘DNA-programmed photoaffinity 
labelling (DPAL; Scheme 4).[75] This approach follows on from previous work by the group of 
Benjamin Cravatt[76,77] and can be used as a means of screening small-molecule binders to protein 
targets. The approach utilises single-chain DNA-encoded small-molecules to capture a protein 
target. After target fishing, a separate complementary single-chain DNA sequence derivatised with 
both an aliphatic diazirine and a fluorophore is introduced. Following DNA hybridisation, photo-
induced covalent tagging, and denaturation steps, the fluorescently-tagged protein mixtures can be 
analysed by multiple methods on gels, by using proteomic mass spectrometry tools or with DNA 
microarrays.  
 
Scheme 4. The process of target capture, photochemical tagging and detection using aliphatic 
diazirines (adapted from Li et al., Angew. Chemie Int. Ed., 2013,	2, 9544 –9549).[75] 
 
 Synthesis of aliphatic diazirines is straight-forward and can be readily accomplished in 




propensity of aliphatic diazirines to undergo rapid b-H atom transfer leading to an alkene product, 
as well as photoinitiated rearrangement to give the diazo isomer which undergoes nucleophilic 
reactions with the solvent, are major limitations of the photochemistry for bimolecular protein 
modification.[67,68] The conformational flexibility of an extended alkyl chain also means that 
aliphatic carbenes are more likely to undergo intramolecular reactions than the more 
conformationally rigid aryl carbenes. These competing intra- and intermolecular processes are 
likely to restrict the use of aliphatic diazirines to systems that pre-associate.  
 
Photoactive reagents that produce electrophiles  
Diazonium salts 
Unlike diazo and diazirine compounds that produce carbenes after photo-initiated loss of N2(g), 
aryldiazonium salts generate electrophilic aryl carbenium ions (Scheme 5).[24] Subsequent attack 
by nucleophilic residues (including primary amines [lysine and N-termini], carboxylates [glutamic 
acid, aspartic acid, and C-termini], alcohols [serine and threonine], and sulfhydryls [cysteine]) or 
by solvent quenching means that the overall mechanism is classified as a photoactivated 
nucleophilic aromatic substitution (photo-SNAr).  
 
Scheme 5. Illustration of the photoactivation of aryldiazonium salts and subsequent reaction of 





 Since the key intermediate is a powerful electrophile, the potential application of 
diazonium salts in bimolecular functionalisation of proteins will be governed by the 
chemoselectivity for different nucleophiles and the relative rates of nucleophilic attack. 
Essentially, if reaction conditions can be identified in which nucleophilic attack from protein 
residues can compete with background quenching reactions, it is conceivable that aryl diazonium 
salts could be useful reagents in the photosynthesis of bioconjugates like ADCs and 




The utility of aryl azides as photoreactive handles for bimolecular protein functionalisation was 
highlighted by our proof-of-concept studies (vide supra). Historically, Doering and Odum were 
the first to report the photochemical synthesis of an azepin ring formation after photolysis of ArN3 
in 1966.[79] Subsequently, Fleet et al. reported the first use of the ArN3 group for PAL in 1969.[15] 
The effects of changing the electron density in the aryl ring were also studied and the earliest 
example of the use meta-NO2 substituted ArN3 reagents is a report on photoaffinity labelling of 
erythrocytes by Staros et al.[80] in 1974. In 1983, Nielsen et al.[25] performed detailed comparisons 
on the photochemical reactivity meta-NO2 substituted ArN3 versus diazocyclopentadienyl and 
ethyl diazomalonyl-derivatives. Experiments concluded that ArN3 derivatives were efficient 
photolabeling reagents of DNA. Young et al.[26] reported the synthesis and photochemical 
properties of pertetrafluoroaryl azides in 1989, with more synthetically versatile para-substituted 




developments have seen the introduction of o-substituted 5-chloro-3,6-difluoro-4-azidopyridine 
reagents.[17] 
The mechanism of aryl azide photoactivation and subsequent reaction with different 
nucleophiles has been studied extensively using chemical analysis, state-of-the-art time-resolved 
spectroscopy, and high level ab initio calculations (Scheme 6).[1,64,65,81–84] Photoactivation of aryl 
azides releases N2(g), initially forming singlet nitrenes (1ArN) in an open-shell 1A2 diradical state. 
This singlet nitrene has a short lifetime of t ~1 ns and can decay by slow intersystem crossing 
(ISC) to form the triplet species (3ArN), by protonation to form the nitrenium ion, or by rapid 
intramolecular rearrangement to give the benzazirine bicycle or the ring-opened ketenimine 
intermediates. At temperatures <180 K, ISC is preferred, whereas at temperatures >230 K 
intramolecular rearrangement dominates.[83,85] Note that for aryl nitrenes, the singlet-to-triplet 
intersystem crossing for 1(p,p*) à 3(p,p*) transitions is a spin-orbit forbidden process. The ISC 
process is not temperature dependent and the corresponding rate constant was found to be kISC = 
(3.2 ± 0.3) x 106 s-1.[64,65,83] As anticipated, the triplet state is lower in energy than the lowest singlet 
state with a relatively large energy gap of ΔGST ~ 75 kJ mol-1, which makes ISC irreversible.[65] 
Thawing frozen solutions of the triplet nitrene gives azobenzene via dimerisation.[65] At ambient 
temperatures, rearrangement of the 1ArN species to give benzazirine and ketenimine intermediates 
is kinetically favoured where bicycle formation to the benzazirene has been identified as the rate 
determining step (ΔGR ~ 23 kJ mol-1 with observed rate constants around kR ~9.9 x 108 s-1).[64,65,83] 
The benzazirene species have not been observed but trapping experiments with ethanethiol as well 
as calculations support this proposed mechanism.[64,86] The ketenimine, also called 
dehydroazepine, has been observed and can be trapped by nucleophiles to form azepines. In the 




diethylamine proceeds with a rate constant of 6.5 x 106 M-1s-1 and after proton transfer gives the 
2-amino-3H-azepine products. Remarkably, the bimolecular reaction with amines outcompetes the 
reaction with H2O which gives the 3H-azepinones (or tautomeric equivalents).[85] Under acidic 
conditions protonation of the 1ArN species gives the nitrenium ions.[87,88] However, with 
unsubstituted 1ArN species, protonation by water proceeds at such a slow rate that it does not 
compete efficiently with the rearrangement reaction. Once formed, the extreme electrophilic 
character of the most aryl nitrenium ions (t ~125 – 240 ps in aqueous solution) causes rapid 
addition of H2O to the para-position forming 4-aminophenol products via nucleophilic aromatic 
substitution mechanisms (SNAr). Rearrangement of singlet nitrenes to the benzazirine and 
ketenimine species can be prevented by substitution of the 2-, 3-, 5- and 6- positions of the aromatic 
group of the aryl azide with fluorine atoms.[67] In particular, ortho substitution with fluorine has 
been shown to affect the rate of ring expansion increasing the thermodynamic barrier to 
rearrangement (ΔGR ~ 35 kJ mol-1) and consequently leading to a longer lifetime of the 1ArN 





Scheme 6. An overview of the current proposed mechanism of aryl azide photoactivation, the 
nitrene rearrangement, intersystem crossing and protonation pathways.[1] 
 
 Mechanistically, photoactivation of aryl azides, rapid rearrangement to the powerful and 
ketenimine electrophile, and subsequent chemoselective reactions with amines that outcompete 
background quenching reactions in aqueous media represents an almost ideal scenario for 
performing bimolecular protein functionalisation reactions (Scheme 7). Our group continues to 
explore the reaction scope of using ArN3 derivatives for tagging mAbs and other biologically 
active molecules with radionuclides, fluorophores and chemotherapeutic drugs. Of particular 
interest would be the development of a site-specific photoradiosynthesis method. Encouragingly, 




chain of a mouse IgG1 mAb using two different, tritium radiolabelled, cross-reactive 6a- and 6b-
(5-azido-2-nitrobenzoyl)amido[17a-3H]estradiol photoactive reagents.[90] We are also actively 
studying the effects of different substituents on the aryl azide ring as well as the role of co-solvents, 
and the influence of other reaction parameters including changes in temperature, pH, ionic 
strengths, counter ion effects, buffer composition and concentrations etc. 
 
Scheme 7. Illustration of the three potential protein conjugation products arising from the 
photoactivation of aryl azides. Note, after photo-induced formation of the singlet aryl nitrene 
intermediate, bimolecular conjugation to proteins can occur via three potential mechanisms: 
nucleophilic attack on ketenimines to give the favoured 2-azepin products, nucleophilic 
substitution via the benzazirene bicycle or by a protonated nitrenium ion intermediate, or direct C-
H, C-C or X-H bond insertion by singlet nitrenes (disfavoured). 
 
Aliphatic azides 
Stoffel et al. were the first to report the use of aliphatic azides as photolabeling reagents in 1978.[22] 
They used tritium radiolabelled 16-azido-[9,10-3H2]palmitic acid as a chemical probe to elucidate 
the topography of proteins of the rhabdovirus VSV (vesicular stomatitis virus) interacting with 
lipid bilayers. Upon photoexcitation with shorter wavelength radiation (~300 nm), aliphatic azides 




two isoenergetic reaction pathways exist for nitrene production from aliphatic azides.[91] Chemical 
reactions of aliphatic nitrenes include: i) nitrene insertion into C−H, C-C and X−H bonds, ii) 
hydrogen abstraction and solvolysis to form amines; and intramolecular rearrangements such as, 
iii) 1,2-alkyl shifts leading to imine formation, and iv) α-H atom abstraction (1,2-hydrogen shift) 
which also leads to formation of a different imine (Scheme 8). These imine intermediates can act 
as electrophiles and react with various nucleophilic residues on proteins. Syzmanski et al. 
performed detailed mechanistic studies on the various reaction products derived from 
photoactivated labelling of proteins with aliphatic azides.[92] They concluded that direct nitrene 
insertion products were not observed in the system and that site-specific and chemoselective 
labelling of cysteine residues via a 1,2-alkyl shift mechanism was favoured. Aliphatic azides have 
yet to be explored as reagents for bimolecular protein conjugation but their tendency to react with 
solvents and undergo facile intersystem crossing to give triplet species are potential drawbacks. 
Nevertheless, the possibility of achieving both chemo- and regioselective coupling to proteins 





Scheme 8. Various reaction pathways arising from the photoactivation and subsequent 
intramolecular and biomolecular reactivity of aliphatic azides.[92] 
 
Photoactive reagents that induce cycloadditions  
Aryl azirines [1,3-dipolar] cycloadditions 
Padwa and Smolanoff were the first to demonstrate photocycloaddition reactions using aryl 
azirines in 1971.[93] Recently, Lim and Qing also explored the potential of aryl azirine-alkene [1,3-
dipolar] cycloadditions in the context of protein labelling by a ‘photo-click’ reaction.[94] 
Photoactivation of aryl 2H-azirines generates highly reactive nitrile ylides via a ring-opening 
mechanism, with high photochemical quantum yields.[93] Nitrile ylides react spontaneously with 
alkenes to produce D1-pyrrolines (Scheme 9). Experiments and computational studies indicate that 
the nitrile ylides are more reactive than nitrile imines that arise from photoexcitation of tetrazoles 
(vide infra).[94,95] This observation appears to be associated with a lower activation energy barrier 
for 1,3-dipolar cycloadditions with nitrile ylides. As such, nitrile ylides preferentially react with 
highly electron deficient alkenes like fumarate. While the aryl azirine ligation process appears to 
be an attractive platform for bimolecular protein functionalisation, two major drawbacks include, 
i) the biorthogonality of the reaction means that pre-modification of the target protein with an 
unsaturated alkene/alkyne is required, and ii) photoactivation requires 302 nm UV light which may 
cause photodamage to protein. However, it may yet be possible to tune the photoactivation step to 
operate at longer wavelengths by inserting auxochromic groups on the phenyl ring or at position 
R1. In addition, two-photon absorption processes have been proposed as a potential ‘low energy’ 





Scheme 9. Photoexcitation of aryl azirines and subsequent 1,3-dipolar addition reactions of the 
nitrile imine intermediate with unsaturated alkenes. 
 
Tetrazoles [1,3-dipolar] cycloadditions – ‘Photo-click’ 
Photoactivation of tetrazoles and the formation of intermediate nitrile imines was first reported by 
Huigsen and Sustmann in 1967.[96] More recently, tetrazole compounds have been developed by 
Qing Lin and co-workers in the context of protein functionalization using a photoactivated 1,3-
dipolar cycloaddition process (Scheme 10).[97–102] The reaction was claimed to be 
bioorthogonal,[101][103] and was given the name ‘photo-click’. However, detailed mechanistic 
studies from two groups have independently refuted this claim and have shown that the nitrile 
imine intermediate can also react with unfunctionalized proteins via nucleophilic attack from 
native nucleophiles including carboxylates, amines, hydroxyl and sulfhydryl groups (Scheme 
10).[104,105] Nevertheless, tetrazoles are potentially useful reagents for bimolecular 
functionalisation of proteins and the group of Dexing Zeng have reported the radiochemical 
synthesis of both 64Cu and [18F]AlF NODAGA complexes functionalised with a tetrazole 
moiety.[106] They used a multi-step approach involving pre-functionalisation of the cetuximab (a 
mAb against human epidermal growth-factor receptor [EGFR]), radiolabelling, and then photo-
induced bioconjugation of the radioactive probe to the mAb, radiotracers were synthesised and 





Scheme 10. Photoexcitation of tetrazoles and subsequent reactions of the nitrile imine using 
functionalized or unmodified proteins via 1,3-dipolar additions with unsaturated alkenes (or 
alkynes), or nucleophilic attack by carboxylates, hydroxyl, amino or sulfhydryl groups with 
unsaturated alkenes. 
 
 One of the elegant features of tetrazole-nitrile imine chemistry is the ability to tune the 
reaction kinetics by lifting the energy level of the highest occupied molecular orbital (HOMO) on 
the tetrazole,[99] or by employing highly strained cyclopropenes (including bicyclic spiro[2.3]hex-
1-enes – bimolecular rate constants, k2 ~34,000 M-1 s-1 which allows accelerated protein 
conjugation in <10 s).[107,108] In addition, the small size of the alkene substrates allows facile, site-
specific incorporation of these reaction by genetic encoding.[98,107,108]  
 Mechanistically, nitrile imine intermediates can undergo rapid 1,3-dipolar cycloaddition 
reactions with either alkene or alkyne substrates. The use of strained dienophiles enhances the rate 
of reaction but the kinetic barrier to cycloaddition is larger than that observed for nitrile ylides. 
However, tetrazoles have another interesting feature – starting from diaryl tetrazoles, 1,3-dipolar 
cycloaddition is fluorogenic and gives substituted pyrazoline products.[102,109] A minor drawback 
of the tetrazole photochemistry is the need to use potentially photo-damaging short wavelength 




potential of tetrazole photochemistry for use in photoradiosynthesis of labelled antibodies for 
immuno-PET, and in the development of ADCs. 
 
o-Quinodimethanes and 2-naptho-quinone-3-methides (oNQMs) – Diels-Alder [4+2] 
cycloadditions 
The groups of Barner-Kowollik[110,111] and Popik[112,113] have recently reported the use of o-
quinodimethanes and 2-naptho-quinone-3-methides, respectively, as reagents for use in photo-
triggered Diels-Alder [4+2] cycloaddition reactions with vinyl groups (Scheme 11). To the best of 
our knowledge, these reagents have yet to be used for protein functionalisation but reports using a 
maleimido-GRGSGR peptide are encouraging.[111] Unlike the majority of the photochemical 
methods described in this article, the photoinduced formation of the reactive diene species is fully 
reversible. For o-quinodimethane reagents, the reaction appears to be bioorthogonal and will 
require the use of a pre-functionalised protein bearing a reactive dienophile. In contrast, 
intermediates produced from the photoactivation of 2-naptho-quinone-3-methide reagents can also 
act as electrophiles and may react with sulfhydryl groups via a Michael-type addition. For both 
classes of reagent, photoactivation occurs at longer wavelengths (320 – 366 nm) and the [4+2] 
cycloadditions with substituted maleimido groups have been reported to be complete in as little as 
15 min. under ambient temperature. It will be intriguing to see if researchers can adapt this 





Scheme 11. Photoexcitation and subsequent coupling reactions of ortho-methylphenylketones 
(top) and 2-naptho-quinone-3-methides (oNQM; bottom) reagents. 
 
Cyclopropenones – photo-triggered de-caging and strain promoted 1,3-dipolar additions  
In 2009, Popik and co-workers reported a metal-free photo-triggered approach for selective 
labelling of live cells.[114] The conjugation chemistry relied on the well-established copper-free 
click strain promoted alkene-azide coupling (SPAAC) reaction between cyclooctynes and an 
azide.[115] Converting a classic SPAAC reaction into a photo-triggered process involved masking 
the dibenzylcyclooctyne (DIBO) group as a cyclopropenone which undergoes photo-induced de-
caging by the loss of carbon monoxide to generate the cyclooctyne in situ (Scheme 12). Other 
researchers have developed the approach further by introducing a three-step ‘photorelease, catch 




also developed a ‘Shine and Click” approach for functionalising the surface of bioactive 
nanoparticles.[117] 
Mechanistically, this photo-triggered de-caging chemistry involves a bioorthogonal, 
thermally-mediated 1,3-dipolar cycloaddition step that requires the use of pre-functionalised 
proteins. The photoactivation step occurs at longer wavelengths (~350 nm) but can also be 
triggered by a multi-photon process.[118] However, the drawback of this approach is the need to 
attach either the masked photo-DIBO group or an azide to the biologically active molecule prior 
to protein conjugation.  
 
Scheme 12. Photo-triggered de-caging and subsequent protein conjugation via a copper-free 
SPAAC ‘click’ reaction. 
 
Photoactive reagents that produce radicals 
Benzophenones 
Benzophenones (BPs) were among the first reagents to be used in PAL.[16] Early studies on the 
mechanism of photochemistry of BPs revealed the photoexcitation leads to reversible formation 
of a relatively long-lived 3(n,p*) triplet state (produced via ISC from the initial formation of either 




Experiments have shown that the triplet species can exist for up to 120 µs before relaxing back to 
the ground state. In part, formation of a triplet species accounts for the low reactivity with water 
and high efficiency for C-H bond insertion reactions with proteins. The nature of the BP excited 
state has been discussed in detail in the comprehensive review from Dormán et al.[120] Advantages 
of BP reagents in photoconjugation chemistry including: i) reversible excitation at wavelengths 
>330 nm (normally 350−360 nm) which is not photodamaging to the protein, ii) the lowest triplet 
state is more reactive than the singlet states, iii) the triplet diradical is highly reactive toward C−H 
insertion bonds (as compared to nitrenes generated from azides), and displays a lower tendency 
toward intramolecular rearrangements than, for example, carbenes, iv) homodimerisation of the 
ketyl radicals to form benzopinacol is the only observed side reaction, v) the diradical reacts 
reversibly with water forming a hydrate that undergoes rapid dehydration to give the original 
ketone, and finally vi) BP compounds are thermally stable under exposure to visible light and under 
ambient conditions employed for normal protein conjugation reactions. These features account for 
the myriad applications of BP derivatives as PAL tools for drug epitope mapping, target protein 
identification, and beyond.[32] While the principle mechanism of protein conjugation using BPs 
involves non-selective C-H bond insertion (Scheme 13), some preference toward methionine 
residues has been reported.[32] However, the very short lifetime of the singlet and triplet 







Scheme 13. Photoactivation of substituted benzophenones followed by rapid ISC to form the 
reactive triplet ketyl diradical. Protein conjugation occurs primarily via classical H-atom 
abstraction and C-H bond insertion. 
 
 A number of groups have reported the use of protein A or protein G derivatives 
functionalised with a BP group for site-specific conjugation to native IgGs.[121–125] The concept 
follows the basic principles of traditional PAL. A complementary binding protein that recognises 
the Fc region of an IgG in a non-specific fashion first pre-associates with the mAb. Then, photo-
induced activation of the BP group leads to a covalent bond between the binding protein and the 
IgG. Although this is a powerful and general strategy for attaching different drugs, radionuclides 
or fluorophores to a mAb, binding to the Fc region can have a detrimental impact on the 
pharmacokinetics of the protein construct. 
  
Thiyl radicals – photolysis of disulfides and thiol-ene / thiol-yne reactions 
It has long been known that UV irradiation of mAb and other proteins can induce homolytic 
cleavage of disulfide bonds to give thiyl radicals.[126–129] Indeed, direct UV irradiation of mAbs 
was employed as a method for introducing 99mTc or 188Re radionuclides.[47,48] The disulfide bond 
enthalpy is ~250 kJ mol-1 which makes it around 40% weaker than C-H, C-C, N-H or O-H bonds, 




be enhanced by using pyrene-based reagents.[130,131] Zhou et al. used reverse-phase liquid 
chromatography double-mass spectrometry (RPLC-MS/MS) combined with 1H/2D exchange 
reactions to investigate the photo-stability of biotherapeutic products (as mandated by regulatory 
agencies).[129] Irradiation of IgG1 and IgG2 mAbs was found to induce selective intramolecular H-
atom transfer reactions on the Cys-thiyl radicals. One notable feature was the observation that 
protein aggregation increased on irradiation with high energy UV light (l ~254 nm). As a stand-
alone process, direct irradiation of proteins to form thiyl radicals is unlikely to be a useful route 
toward high yielding protein ligation. However, the process may potentially be coupled to the 
radical-based one-step thiol-ene or two-step thiol-yne reactions to produce a novel bioconjugation 
approach (Scheme 14). 
 
 
Scheme 14. Illustration of the photoactivated homolytic cleavage of disulfide bonds or sulfhydryls 
to initiate a radical-based thiol-ene or thiol-yne conjugation reactions for protein ligation. 
 The thiol-yne was discovered in 1949.[132] More recently, Li et al. employed the thiol-yne 
radical reaction for site-specific protein labelling via genetic encoding of an alkynyl-L-lysine 
(alkynyl-pyrrolysine) analogue.[133] The photoactivation step employed 2,2-dimethoxy-2-




hours of photolysis, the conjugation yields was estimated at ~60%. Although current conjugation 
methods that employ thiyl-radical mechanisms may not be competitive with other photoactive 
reagents, the use of radicals opens the intriguing possibility of using photo-induced living 
polymerisation methods to build complex protein co-polymers.[134–136] 
 
9,10-phenanthrenequinones – biradical [4+2] cycloaddition 
In 2018, Li et al. reported a fluorogenic, bioorthogonal ‘photo-click’ reaction between 9,10-
phenanthrenequinone (PQ) derivatives and electron-rich alkenes (Scheme 15).[137] The reaction 
was initiated with visible light and photoactivation generates a range of biradical species that 
undergo bioorthogonal [4+2] cycloaddition reactions with vinyl groups.[138] The approach required 
pre-modification of the protein (bovine serum albumin [BSA] or lysozyme) with an alkene, but in 
principle if this chemistry is coupled with genetic encoding methods, it would allow both chemo- 
and regioselective protein ligation. Interestingly, the reaction proceeded under biocompatible 
conditions (in the presence of live cells), with no side reactions observed with water or other 
common nucleophiles. Kinetic studies using different light sources gave bimolecular rate constants 
in the range 0.28 to 2.76 M-1 s-1. Although reaction rates are slower than some other photochemical 
reactions, the relatively high molar absorption coefficient of ε ~1472 M-1 cm-1 at 430 nm means 






Scheme 15. Photoactivated [4+2] cycloaddition reactions between derivatised 9,10-
phenanthrenequinones and pre-functionalised proteins bearing alkenes.  
 
Future perspectives 
The reagents and tools of photochemistry are valuable resources for the development of innovative 
bioconjugation processes that have the potential to solve some of the practical and technological 
issues encountered with traditional thermally-mediated coupling chemistries. For most 
photochemical reactions, the challenge remains to balance the (often) extreme reactivity of the 
photo-induced intermediate with the need to perform chemo- and regioselective conjugations. 
Many reagents exist that upon photoexcitation produce reactive carbenes, nitrenes, nitrile ylides, 
nitrile imines, electrophiles, radicals or dienes. Progress has been made on site-selective (and even 
enantioselective[139]) photochemical methods but more work is required before photosynthetic 
approaches become the tools of choice for functionalising biologically active molecules. 
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